戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nificantly lower than that induced by either biguanide.
2        Serine synthesis was not inhibited by biguanides.
3 K) is known to be a major cellular target of biguanides.
4 ga officinalis L.) led to the development of biguanides.
5 osphorylation are regulated independently by biguanides.
6 eated to determine whether polyhexamethylene biguanide, 0.02%, chlorhexidine digluconate, 0.02%, hexa
7      The structure-activity relationships of biguanides 5 and putative metabolites 8 are discussed.
8 vide a mechanism of tumor cell resistance to biguanide activity.
9 ed drugs (insulins, sulfonylureas, glinides, biguanides, alpha-glucosidase inhibitors, thiazolidinedi
10                     We now report that novel biguanide and bisguanidine polyamine analogues are poten
11 s, C-fiber responses to injections of phenyl biguanide and lactic acid and to constant-pressure lung
12 ent, local irrigation with polyhexamethylene biguanide, and the systemic administration of voriconazo
13 , azines, amidines, guanidines, vinamidines, biguanides, and phosphazenes.
14 tions, synthetic lethality strategies, novel biguanides, and the use of predictive biomarkers.
15       We reported that (bis)guanidines, (bis)biguanides, and their urea- and thiourea isosteres are p
16         These defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS, when
17 ord and colleagues show, paradoxically, that biguanides are more effective in the treatment of mouse
18 anipulation that can enhance the efficacy of biguanides as antineoplastic agents that target cancer c
19                            Polyhexamethylene biguanide can inhibit PCR, and we suggest that specimen
20 have investigated the effects of the diamino biguanide compound metformin and of hyperglycemia on MG
21 Bacillus subtilis , to develop guanidine and biguanide compounds with up to 20-fold increased potency
22 ese results suggest that cellular effects of biguanides depend on their metal-binding properties.
23 ed us to identify an anti-cancer drug of bis-biguanide dihydrochloride (BBD) as potent anti-mycobacte
24                                          The biguanide drug metformin has recently been found to impr
25                                          The biguanide drug metformin is widely prescribed to treat t
26                                          The biguanide drug metformin stimulates AMP-activated protei
27                        Thiazolidinedione and biguanide drugs, which are used to increase insulin sens
28 r cell lines, the global metabolic impact of biguanides during the process of neoplastic transformati
29            Metformin, an insulin-sensitizing biguanide, enhances peripheral insulin action and lowers
30              Metformin (MF), a member of the biguanide group, has been shown to facilitate osteoblast
31 he delocalization of cationic charges in the biguanide groups of PolyMet reduces the toxicity of PEI
32                 In contrast, in breast CSCs, biguanides have a modest effect on glycolytic and TCA cy
33               Despite of their plant origin, biguanides have not been reported in plants.
34 g) or the 5-HT(3) agonist l-(m-chlorophenyl)-biguanide hydrochloride (mCPBG; 5.0-15.0 mg/kg), alone o
35       Although phenformin is the more potent biguanide in both systems, the metabolic profiles of the
36 ddition, the possible biosynthetic routes of biguanide in these plant foods are discussed.
37  facilitate studies on metformin and related biguanides in cancer prevention and treatment.
38 d to increased interest in possible roles of biguanides in cancer prevention and/or treatment.
39 ular depletion of aPKC (>90%) led to loss in biguanide-induced aPKC phosphorylation, it had no effect
40  for serine to allow cells to compensate for biguanide-induced decrease in oxidative phosphorylation
41 ional PKCs caused a significant reduction in biguanide-induced GU.
42                                              Biguanide-induced inactivation of mTORC1 subsequently in
43                          We demonstrate that biguanides inhibit growth by inhibiting mitochondrial re
44 c profiles are consistent with the idea that biguanides inhibit mitochondrial complex 1, but they ind
45          Metformin (MF), a second-generation biguanide, is a commonly used oral antidiabetic drug tha
46 tochondrial oxidative phosphorylation (using biguanides) led to a complex response that could improve
47 he 5-HT3 receptor agonist 1-m-(chlorophenyl) biguanide (m-CPGB, 1 microM), markedly increased (300%)
48                                              Biguanides may exploit specific metabolic vulnerabilitie
49  been proposed that this compound or related biguanides may have antineoplastic activity.
50  by the selective agonist 1-(m-chlorophenyl)-biguanide (mCPBG).
51 d the 5-HT3 receptor agonist, m-chlorophenyl-biguanide (mCPBG; 250, 500, or 1000 ng).
52 % [14 of 15 isolates]) and polyhexamethylene biguanide (median growth grade, 0.0; kill incidence rate
53                                              Biguanide/metal interactions are stabilized by extensive
54 CT1) affects the response to the widely used biguanide metformin (see the related article beginning o
55 onse to the sulphonylurea gliclazide and the biguanide metformin differed in HNF-1alpha diabetes and
56                                          The biguanide metformin had no effect on either enzyme, wher
57     In recent decades, the antihyperglycemic biguanide metformin has been used extensively in the tre
58 ion between TEA and Arg was found, while the biguanide metformin was able to strongly inhibit uptake
59                                   Use of the biguanide metformin, an AMPK activator, is associated wi
60  AMPK activators, including the antidiabetic biguanide metformin, inhibited FXR agonist induction of
61                                          The biguanide phenformin has been shown to independently dec
62 tabolic effects of metformin and the related biguanide phenformin have been investigated in establish
63 ation of the ERK inhibitor SCH772984 and the biguanide phenformin.
64                          Met and its related biguanide, phenformin, stimulated AMPK activation/phosph
65                            Polyhexamethylene biguanide (PHMB) is a disinfectant used in swimming pool
66  widely used antimicrobial polyhexamethylene biguanide (PHMB) kills bacteria selectively over host ce
67 lyethyleneimine (PEI) and poly(hexamethylene biguanide) (PHMBG) and are prepared by a two-step proced
68 f chemosensitive vagal afferents with phenyl biguanide produced an increase (n=3), decrease (n=2), or
69               A total of 34 analogues of the biguanide PS-15 (5s), a prodrug of the diaminotriazine W
70  The objective of this study was to quantify biguanide related compounds (BRCs) in experimentally or
71      Nonetheless, the mechanism of action of biguanides remains imperfectly understood.
72                                 Notably, the biguanide sensitivity of cancer cells with mtDNA mutatio
73 et-induced AMPK signaling but only repressed biguanide-stimulated GU by approximately 20%.
74 tineoplastic effects of phenformin (a potent biguanide structurally related to metformin).
75 ication of the metal-liganding groups of the biguanide structure, supporting recent data that AMPK an
76                                              Biguanides such as metformin are widely used worldwide f
77                                              Biguanides such as metformin have previously been shown
78                                              Biguanides, such as the diabetes therapeutics metformin
79                                              Biguanides, such as the diabetes therapeutics metformin
80 d pressure, statins adjusted for lipids, and biguanides, sulfonylureas, alpha-glycosidase inhibitors
81 kers, diuretics, nitrates, statins, insulin, biguanides, sulfonylureas, aspirin, and other nonsteroid
82 eported a series of (bis)guanidines and (bis)biguanides that are potent inhibitors of LSD1 and induce
83  and upregulation of ACAD10 are required for biguanides to reduce viability in melanoma and pancreati
84 vidence that this intrinsic property enables biguanides to regulate AMPK, glucose production, glucone
85 ring the process of cellular transformation, biguanide treatment prevents the boost in glycolytic int
86 anced the tumor growth-inhibitory actions of biguanide treatment.
87                            Polyhexamethylene biguanide was the only topical drug that demonstrated PC
88  in reducing glucose production has been the biguanides, which include phenformin and metformin, the
89                               Metformin is a biguanide widely prescribed to treat Type II diabetes th
90                                 Metformin, a biguanide widely used in the treatment of type II diabet

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。